

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/855,632		05/14/2001	Robert E. Reiter	30435.69USD4	2142
26941	7590	10/18/2002			
MANDEL	& ADRI	ANO	EXAMINER		
55 SOUTH	LAKE AV	ENUE	HELMS, LARRY RONALD		
SUITE 710		101		TIDDIVID, DI IIG	
PASADENA, CA 91101				ART UNIT	PAPER NUMBER
				1642	10
				DATE MAILED: 10/18/2002	16

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	Application No. 09/855,632	REITER ET AL.					
Office Action Summary	Examiner	Art Unit					
·	Larry R. Helms	1642					
The MAILING DATE of this communication app							
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on							
, <u> </u>	s action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4)⊠ Claim(s) 1 and 53-86 is/are pending in the app	lication						
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to	or election requirement						
8)⊠ Claim(s) <u>1, 53-86</u> are subject to restriction and/or election requirement. Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the	,						
11) The proposed drawing correction filed on	is: a) ☐ approved b) ☐ disappro	ved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.							
12) ☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents	have been received.						
2. Certified copies of the priority documents	have been received in Application	on No					
 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received.							
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s)							
1) Notice of References Cited (PTO-892)	4) 🔲 Intonúa S	(PTO 442) Pages No.(5)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) Patent Application (PTO-152)					

Application/Control Number: 09/855,632

Art Unit: 1642

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claim 1, drawn to an antibody which binds PSCA, classified in class 530, subclass 388.85.
 - Claims 53-69, drawn to an anti-idiotypic antibody, classified in class 530, subclass 387.2.
 - III. Claims 70-86, drawn to a method of inducing an immune response, classified in class 424, subclass 131.1.
- 2. The inventions are distinct, each from the other because of the following reasons:

 Inventions of Groups I and II represent separate and distinct products which are
 made by materially different methods. The antibody of Group I binds the PSCA protein
 whereas the anti-idiotypic antibody binds a different antigen of the antibody to PSCA.

 The antibody is produced by immunization with the PSCA protein while the anti-idiotypic
 antibody is made by immunization with the antibody or regions of the antibody to PSCA.

The examination of all groups would require different searches in the U.S. Patent shoes and the scientific literature and would require the consideration of different patentability issues. Thus the inventions I and II are patentably distinct.

Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially

Application/Control Number: 09/855,632

Art Unit: 1642

different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the claims of Group III recite a method of inducing an immune response which can be performed with any antibody as well as administration of an antigen of the PSCA protein. In addition, the anti-idiotypic antibody can be used in a materially different method such as to determine the structure of the binding site for developing peptides for therapy that mimic the binding site.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and different classifications, restriction for examination purposes as indicated is proper.
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(l).
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Larry R. Helms, Ph.D., whose telephone number is (703) 306-5879. The examiner can normally be reached on Monday through Friday from 7:00 am to 4:30 pm, with alternate Fridays off. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of

Art Unit: 1642

this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

6. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 308-4242.

Respectfully,

Larry R. Helms Ph.D.

703-306-5879

LARRY HELMS